Christopher P. Guise

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

Fanying Meng, James Evans, Deepthi Bhupathi et al. · Molecular Cancer Therapeutics · 2011 · 203 citations

Pharmacotherapy, Redox Biology, Oxidative Stress +18

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

Christopher P. Guise, Maria R. Abbattista, Rachelle S. Singleton et al. · Cancer Research · 2010 · 185 citations · Full text

Cancer Metabolism, Reductive Stress, Tumor Hypoxia +15

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Linda Spiegelberg, Ruud Houben, Raymon Niemans et al. · Clinical and Translational Radiation Oncology · 2019 · 114 citations · Full text

Clinical Progress, Pharmacotherapy, Tumor Biology +19

Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: A role for NADPH:cytochrome P450 oxidoreductase under hypoxia

Christopher P. Guise, Anderson T. Wang, Anke Theil et al. · Biochemical Pharmacology · 2007 · 87 citations

Reductive Stress, Prodrug Pr-104a, Biochemistry +9

DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity

Rachelle S. Singleton, Christopher P. Guise, Dianne M. Ferry et al. · Cancer Research · 2009 · 82 citations · Full text

Chemoprevention Strategy, Tumor Growth Delay, Redox Biology +24